Product
Valoctocogene roxaparvovec
Aliases
BMN 270, valoctocogene roxaparvovec
5 clinical trials
2 indications
Indication
Hemophilia AIndication
Hemophilia A with inhibitorClinical trial
A Phase 3 Open-Label, Single-Arm Study To Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A Patients With Residual FVIII Levels ≤ 1 IU/dL Receiving Prophylactic FVIII InfusionsStatus: Active (not recruiting), Estimated PCD: 2020-11-16
Clinical trial
A Phase 3b, Single Arm, Open-Label Study to Evaluate the Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII, With Prophylactic Corticosteroids in Hemophilia A PatientsStatus: Active (not recruiting), Estimated PCD: 2023-01-27
Clinical trial
GENEr8-JPN: A Phase 3 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Japanese Hemophilia A Patients With Residual FVIII Levels ≤ 1 IU/dL Receiving Prophylactic FVIII InfusionsStatus: Active (not recruiting), Estimated PCD: 2025-03-01
Clinical trial
A Phase 1/2, Dose-Escalation, Safety, Tolerability and Efficacy Study of Valoctocogene Roxaparvovec, an Adenovirus-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Patients With Severe Haemophilia AStatus: Active (not recruiting), Estimated PCD: 2024-03-01
Clinical trial
A Phase 1/2 Safety, Tolerability, and Efficacy Study of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A Patients With Active or Prior InhibitorsStatus: Recruiting, Estimated PCD: 2029-02-01